H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on MetaVia today and set a price target of $12.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Andrew Fein’s rating is based on MetaVia’s strategic positioning in the metabolic disease space, particularly through its promising drug candidates DA-1726 and DA-1241. The company is leveraging recent trends in the MASH treatment landscape, which favor combination therapies, by pursuing a partnership to develop DA-1241 in conjunction with liver-directed therapies. This approach not only reduces development risks but also aligns MetaVia with the emerging standard of care, enhancing its competitive advantage.
Furthermore, MetaVia’s lead asset, DA-1726, has shown significant potential by achieving notable weight loss and metabolic improvements in early trials, which could attract patients switching from other therapies. The positive Phase 2a results for DA-1241, combined with the FDA’s growing acceptance of noninvasive liver biomarkers as surrogate endpoints, suggest an accelerated development timeline and increased partnering opportunities. These factors collectively support Fein’s Buy rating, highlighting MetaVia’s potential for growth and innovation in the field.
In another report released on November 7, Maxim Group also maintained a Buy rating on the stock with a $5.00 price target.